US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors
Patent 10239837 was granted and assigned to Regenacy Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+212 characters)
Article
Patent abstract
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
102398370
Date of Patent
March 26, 2019
0Patent Application Number
157197480
Date Filed
September 29, 2017
0Patent Citations Received
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
102398370
Date of Patent
March 26, 2019
0Patent Application Number
157197480
Date Filed
September 29, 2017
0Patent Citations Received
Patent Primary Examiner
Edits on 11 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10239837
Date of patent
March 26, 2019
Patent application number
15719748
Date Filed
September 29, 2017
Patent primary examiner
Find more entities like US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
